Study: Remdesivir offers no clinical benefit for COVID-19, extends hospital stay for many – UPI.com

Treatment with the the antiviral drug remdesivir offered no clinical benefit to patients hospitalized with COVID-19, even prolonging their stay in healthcare facilities, a study published Thursday by JAMA Network Open found. Patients treated with the drug, which originally was developed to treat the Ebola virus, stayed in the hospital an average of roughly six days, while those who did not receive it were discharged after about three days, the data showed.

Source: Study: Remdesivir offers no clinical benefit for COVID-19, extends hospital stay for many – UPI.com